Shopping Cart 0
Cart Subtotal
AED 0

Sorrento Therapeutics Inc (SRNE) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376

Details

Sorrento Therapeutics Inc (SRNE)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sorrento Therapeutics Inc (Sorrento), formerly QuikByte Software Inc, is a clinical stage, antibody-centric, biopharmaceutical company. It focuses on the treatment of chronic cancer pain as well as immunology and infectious diseases. The company's immuno-oncology (I-O) portfolio comprises of a broad fully human antibody library (G-MAB), clinical stage chimeric antigen receptor-T cells (CAR-T), intracellular targeting antibodies (iTAbs), antibody-drug conjugates (ADC), and an oncolytic virus (Sephrehvir). Sorrento provides treatment for multiple myeloma, metastatic liver tumors and solid tumors. It works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.

Sorrento Therapeutics Inc Key Recent Developments

Jan 14,2019: Scilex Announces ZTlido Insurance Coverage for ~100 Million Insured Lives(1)

Jan 14,2019: Scilex Announces Addition of ZTlido to Express Scripts National Formularies

Nov 08,2018: Sorrento Therapeutics closes five-year term loan financing for up to USD 150 million

Nov 07,2018: TriSalus Life Sciences Pressure-Enabled Drug Delivery (PEDD) Significantly Increased Therapeutic Effect of Anti-CEA CAR-T in Pancreatic Cancer Patients with Liver Metastases

Nov 01,2018: Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Sorrento Therapeutics Inc-Key Facts

Sorrento Therapeutics Inc-Key Employees

Sorrento Therapeutics Inc-Key Employee Biographies

Sorrento Therapeutics Inc-Major Products and Services

Sorrento Therapeutics Inc-History

Sorrento Therapeutics Inc-Company Statement

Sorrento Therapeutics Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2-Company Analysis

Company Overview

Sorrento Therapeutics Inc-Business Description

Sorrento Therapeutics Inc-Corporate Strategy

Sorrento Therapeutics Inc-SWOT Analysis

SWOT Analysis-Overview

Sorrento Therapeutics Inc-Strengths

Sorrento Therapeutics Inc-Weaknesses

Sorrento Therapeutics Inc-Opportunities

Sorrento Therapeutics Inc-Threats

Sorrento Therapeutics Inc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Sorrento Therapeutics Inc, Recent Deals Summary

Section 5-Company's Recent Developments

Nov 08, 2018: Sorrento Therapeutics closes five-year term loan financing for up to USD 150 million

Nov 07, 2018: TriSalus Life Sciences Pressure-Enabled Drug Delivery (PEDD) Significantly Increased Therapeutic Effect of Anti-CEA CAR-T in Pancreatic Cancer Patients with Liver Metastases

Nov 01, 2018: Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma

Sep 27, 2018: Sorrento Therapeutics to Present at the Leerink Partners Roundtable Series 10/3/2018

Sep 10, 2018: Sorrento Therapeutics Subsidiary, Scilex, Raises USD 140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido Pain Medication

Jul 05, 2018: Sorrento buys Kimberly-Clark's Sofusa lymphatic delivery platform

Apr 23, 2018: Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on Unite to Cure

Mar 28, 2018: Sorrento Therapeutics Chairman/CEO update to stockholders

Mar 19, 2018: Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018

Feb 05, 2018: Sorrento Therapeutics Chairman/CEO letter to stockholders

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Sorrento Therapeutics Inc, Performance Chart (2013-2017)

Sorrento Therapeutics Inc, Ratio Charts

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Sorrento Therapeutics Inc, Key Facts

Sorrento Therapeutics Inc, Key Employees

Sorrento Therapeutics Inc, Key Employee Biographies

Sorrento Therapeutics Inc, Major Products and Services

Sorrento Therapeutics Inc, History

Sorrento Therapeutics Inc, Subsidiaries

Sorrento Therapeutics Inc, Joint Venture

Sorrento Therapeutics Inc, Key Competitors

Sorrento Therapeutics Inc, Ratios based on current share price

Sorrento Therapeutics Inc, Annual Ratios

Sorrento Therapeutics Inc, Annual Ratios (Cont...1)

Sorrento Therapeutics Inc, Interim Ratios

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Sorrento Therapeutics Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Sorrento Therapeutics Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

CytRx Corp

Halozyme Therapeutics Inc

Exelixis Inc

Anthera Pharmaceuticals Inc

Company Profile

Company Profile Title

Sorrento Therapeutics Inc (SRNE)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sorrento Therapeutics Inc (Sorrento), formerly QuikByte Software Inc, is a clinical stage, antibody-centric, biopharmaceutical company. It focuses on the treatment of chronic cancer pain as well as immunology and infectious diseases. The company's immuno-oncology (I-O) portfolio comprises of a broad fully human antibody library (G-MAB), clinical stage chimeric antigen receptor-T cells (CAR-T), intracellular targeting antibodies (iTAbs), antibody-drug conjugates (ADC), and an oncolytic virus (Sephrehvir). Sorrento provides treatment for multiple myeloma, metastatic liver tumors and solid tumors. It works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.

Sorrento Therapeutics Inc Key Recent Developments

Jan 14,2019: Scilex Announces ZTlido Insurance Coverage for ~100 Million Insured Lives(1)

Jan 14,2019: Scilex Announces Addition of ZTlido to Express Scripts National Formularies

Nov 08,2018: Sorrento Therapeutics closes five-year term loan financing for up to USD 150 million

Nov 07,2018: TriSalus Life Sciences Pressure-Enabled Drug Delivery (PEDD) Significantly Increased Therapeutic Effect of Anti-CEA CAR-T in Pancreatic Cancer Patients with Liver Metastases

Nov 01,2018: Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Sorrento Therapeutics Inc-Key Facts

Sorrento Therapeutics Inc-Key Employees

Sorrento Therapeutics Inc-Key Employee Biographies

Sorrento Therapeutics Inc-Major Products and Services

Sorrento Therapeutics Inc-History

Sorrento Therapeutics Inc-Company Statement

Sorrento Therapeutics Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2-Company Analysis

Company Overview

Sorrento Therapeutics Inc-Business Description

Sorrento Therapeutics Inc-Corporate Strategy

Sorrento Therapeutics Inc-SWOT Analysis

SWOT Analysis-Overview

Sorrento Therapeutics Inc-Strengths

Sorrento Therapeutics Inc-Weaknesses

Sorrento Therapeutics Inc-Opportunities

Sorrento Therapeutics Inc-Threats

Sorrento Therapeutics Inc-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Sorrento Therapeutics Inc, Recent Deals Summary

Section 5-Company's Recent Developments

Nov 08, 2018: Sorrento Therapeutics closes five-year term loan financing for up to USD 150 million

Nov 07, 2018: TriSalus Life Sciences Pressure-Enabled Drug Delivery (PEDD) Significantly Increased Therapeutic Effect of Anti-CEA CAR-T in Pancreatic Cancer Patients with Liver Metastases

Nov 01, 2018: Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma

Sep 27, 2018: Sorrento Therapeutics to Present at the Leerink Partners Roundtable Series 10/3/2018

Sep 10, 2018: Sorrento Therapeutics Subsidiary, Scilex, Raises USD 140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido Pain Medication

Jul 05, 2018: Sorrento buys Kimberly-Clark's Sofusa lymphatic delivery platform

Apr 23, 2018: Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on Unite to Cure

Mar 28, 2018: Sorrento Therapeutics Chairman/CEO update to stockholders

Mar 19, 2018: Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018

Feb 05, 2018: Sorrento Therapeutics Chairman/CEO letter to stockholders

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Sorrento Therapeutics Inc, Performance Chart (2013-2017)

Sorrento Therapeutics Inc, Ratio Charts

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Sorrento Therapeutics Inc, Key Facts

Sorrento Therapeutics Inc, Key Employees

Sorrento Therapeutics Inc, Key Employee Biographies

Sorrento Therapeutics Inc, Major Products and Services

Sorrento Therapeutics Inc, History

Sorrento Therapeutics Inc, Subsidiaries

Sorrento Therapeutics Inc, Joint Venture

Sorrento Therapeutics Inc, Key Competitors

Sorrento Therapeutics Inc, Ratios based on current share price

Sorrento Therapeutics Inc, Annual Ratios

Sorrento Therapeutics Inc, Annual Ratios (Cont...1)

Sorrento Therapeutics Inc, Interim Ratios

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Sorrento Therapeutics Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Sorrento Therapeutics Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

CytRx Corp

Halozyme Therapeutics Inc

Exelixis Inc

Anthera Pharmaceuticals Inc